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Cancer cells demonstrate numerous genetic aberrations. Despite this genetic complexity, it is hypothesized that 
cancer cells are often addicted to a single oncogenic driver 
such that inhibition of this single target would lead to cell 
death.1 Data collected from patients with adenocarcinoma by 
the Lung Cancer Mutation Consortium demonstrate a signifi-
cant number of patients harboring distinct oncogenic drivers, 
many of which may be amenable to targeted therapies.2 Two 
current areas of intense investigation are to match targeted 
therapies to a growing list of selected oncogene aberrations in 
patients with non–small-cell lung cancer (NSCLC) and also to 
understand mechanisms of resistance to these targeted thera-
pies so that resistance can be overcome or potentially delayed 
with new drugs or drug combinations.
ALK
The recent approval of crizotinib for anaplastic lym-
phoma kinase (ALK) positive NSCLC patients ushered in the 
first Food and Drug Administration companion diagnostic for 
NSCLC, ALK fluorescence in situ hybridization (FISH). ALK 
break-apart FISH was, and still is, the diagnostic test used for 
entry into the completed and ongoing crizotinib studies and 
remains the only prospectively validated test for this drug. Dr. 
Garcia described other testing methods that are in develop-
ment, including immunohistochemistry (IHC) and bright field 
in situ hybridization (BISH), both of which might have advan-
tages relating to ease of adoption. Whether either would also 
have an advantage in terms of cost effectiveness is debatable 
as this will depend on the ultimate cost of a validated assay. 
IHC takes advantage of the lack of ALK expression in normal 
lung tissue, or in cancers without an ALK gene rearrangement, 
by evaluating levels of ALK protein expression. BISH uses a 
similar strategy to FISH by evaluating the distance between 
chromagen-labeled probes that are homologous to the 5′ and 
3′ ends of the ALK gene to detect evidence of an inversion or 
translocation involving the ALK gene, but does so without the 
need for a  fluorescence microscope. Although early studies 
suggest good concordance between these tests and ALK FISH 
within single centers, the need for both standardized protocols 
for the multiple commercially available ALK antibodies for 
IHC and the need for standardized scoring systems for both 
BISH and IHC were highlighted.
Drs. Doebele and Shaw presented data on observed 
mechanisms of resistance to crizotinib in ALK positive NSCLC 
patients who underwent biopsy at the time of progression.3,4 
Both groups observed a diverse array of ALK kinase domain 
mutations. The diversity of mutations is reminiscent of those 
observed in BCR-ABL after resistance to imatinib, rather than 
the dominant T790M mutation observed in epidermal growth 
factor receptor (EGFR) mutant patients after EGFR kinase 
inhibitor resistance. ALK resistance mutations were observed 
in 20% to 40% of patients. Copy number gain through ampli-
fication of the ALK gene fusion was observed in 5% to 20% 
of patients. The University of Colorado series observed 36% 
of patients with the presence of an EGFR or v-Ki-ras2 Kirsten 
rat sarcoma viral oncogene homolog (KRAS) activating muta-
tion and/or the absence of an ALK gene rearrangement in the 
resistance biopsy, suggesting the emergence of a clonally dis-
tinct population of cells that were no longer solely dependent 
on ALK signaling. The Massachusetts General Hospital series 
observed increased phosphorylated EGFR in the absence of 
an activating mutation in a subset of patients. Previously, some 
cell lines derived from crizotinib-naive ALK+ patients have 
also demonstrated increased EGFR and/or v-erb-b2 erythro-
blastic leukemia viral oncogene homolog 2 (HER2) signal-
ing in the absence of activating mutations, with a combination 
of agents directed against both ALK and EGFR/HER2 sig-
naling required to achieve growth inhibition.4,5 In addition, 
from the Massachusetts General Hospital series, v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) 
gene amplification was observed as a mechanism of resistance 
in two patients. Collectively, these data suggest that resistance 
to crizotinib in some patients may emerge through total or par-
tial reliance on other oncogenic drivers, and the primary sig-
nificance of this is that these patients would not be expected to 
benefit from monotherapy with a more potent ALK inhibitor.
In contrast, patients with ALK kinase domain resistance 
mutations and copy number gain of the ALK fusion gene are 
likely to still retain oncogene addiction to ALK signaling. 
Thus, these patients may be much more likely to benefit from a 
more potent, next-generation, ALK kinase inhibitor. Drs. Shaw, 
Gettinger, and Gandhi presented preclinical data on three such 
ALK inhibitors: LDK378 (Novartis, Basel, Switzerland), 
AP26113 (Ariad, Cambridge, MA), and CH5424802 (Chugai), 
respectively. In xenograft models, all three drugs demonstrated 
activity against unmutated EML4-ALK whereas LDK378, and 
AP26113 also demonstrated activity against xenografts bear-
ing the known C1156Y and L1196M crizotinib-resistance 
mutations, respectively. Interestingly, AP26113 demonstrates 
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activity against mutant EGFR, which could be applicable 
in patients who demonstrate this mechanism of resistance, 
although the IC
50s
 (median inhibition concentration) associated 
with EGFR inhibition were significantly higher than for ALK 
inhibition. Currently, all three compounds are being evaluated 
in early-phase studies in both crizotinib-naive and crizotinib-
resistant patients. AP26113 is also being evaluated in cancers 
with a c-ros oncogene 1, receptor tyrosine kinase (ROS1) gene 
rearrangement (see below). Dr. Camidge described a phase 
I study combining crizotinib with dacomitinib (PF-299804), 
Pfizer’s irreversible pan-HER inhibitor. This drug combination 
was initially developed to address the common mechanisms 
of acquired resistance in EGFR mutant NSCLC (T790M and 
met proto-oncogene (MET) gene amplification), however, it 
may also have a role in crizotinib resistance occurring through 
increased EGFR and/or HER2 signaling and accrual to a dedi-
cated ALK+ crizotinib-resistant cohort is being considered. 
Given the diversity of resistance mechanisms to crizotinib 
and their potential impact on subsequent treatment strategies 
directly and solely against ALK, it will be critical to evaluate 
the mechanism of crizotinib resistance in the patients treated 
within all these studies.
ROS1
ROS1 is a receptor tyrosine kinase that is homologous 
to ALK. Similar to the ALK FISH break-apart assay, the 
break-apart FISH assays, according to Dr. Garcia, were meant 
to evaluate the deletions, inversions, and translocations that 
can fuse the 3′ region encoding the kinase domain of the ROS1 
oncogene to a variety of 5′ fusion partners including CD74, 
EZR, GOPC (FIG), LRIG3, SL34A2, SDC4, and TPM3.6,7 The 
incidence across multiple studies suggests that ROS1 gene 
fusions occur in slightly more than 1% of NSCLC. In vitro 
data suggest that ROS1 can transform cells and that inhibition 
with the ALK inhibitors, crizotinib, or TAE684, blocks cell 
proliferation and induces cell-cycle arrest in G1 via inhibition 
of downstream signaling cascades through SHP2, AKT, and 
ERK.7,8 Treatment with crizotinib in an expanded cohort of the 
Pfizer phase I trial of PF-02341066 (crizotinib) induced tumor 
shrinkage in two patients with ROS1 gene rearrangements, 
one with an syndecan 4 (SDC4–ROS1) rearrangement, and 
the other unknown, suggesting that these gene rearrangements 
may be a suitable target for inhibitors such as crizotinib.6,8
BRAF
 The v-raf murine sarcoma viral oncogene homolog B1 
(BRAF) encodes a nonreceptor serine/threonine kinase that can 
activate the MAPK pathway. Activating mutations in BRAF 
occur in approximately 3% of NSCLC patients, much lower 
than that observed in melanoma, where investigations have 
recently led to the Food and Drug Administration approval of 
vemurafenib in this disease.9,10 The most common mutation, 
V600E, is seen in approximately 50% of NSCLC patients with 
a BRAF mutation, whereas the other less-common non-V600E 
mutations (G469A and D594G) comprise the other half. Drs. 
Miller and Riely reported on preclinical and clinical activity 
of dabrafenib (GSK2118436; Glaxo-SmithKline, Brentford, 
Middlesex, United Kingdom) and vemurafenib (PLX4032; 
Genentech, South San Francisco, CA), respectively. Both drugs 
are being investigated in a number of BRAF mutant malignan-
cies. One significant safety concern with this class of drug is 
the induction of squamous cell carcinomas of the skin in less 
than 20% of patients, which typically occur within weeks to 
months of initiation of the drug and are treated successfully 
with curative-intent curettage.10 One interesting mechanism of 
intrinsic resistance that has come to light in BRAF mutation-
positive colorectal cancer is the activation of EGFR via inhi-
bition of BRAF, which inhibits a phosphatase that typically 
inactivates EGFR.11 This finding highlights a potential pitfall of 
transferring a targeted therapy from one cancer type to another.
SUMMARY
As the repertoire of targetable genetic abnormalities 
increase, we will need to develop mechanisms that are both practi-
cal and reliable to identify patients with relatively rare oncogenes. 
The broad range of crizotinib-resistance mechanisms observed in 
ALK+ NSCLC suggests that diversity will re-emerge as a major 
issue even from initially largely molecular uniform tumors in the 
acquired-resistance setting. Whether therapies directed against 
resistance mechanisms should be employed only at the time of 
resistance, or earlier to delay the emergence of resistance, will 
need to be addressed over the next few years. Factors influencing 
the choice between these two strategies will include the tolerabil-
ity of the treatment regimen and whether technology looking, for 
example, for low levels of resistance mechanisms in treatment-
naive patients, will evolve to allow us to accurately predict which 
patient is more likely to employ a specific mechanism of resis-
tance before it becomes clinically apparent.
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